Q-omics provides the consensus-scored RAPGEF1 profile across patient tissues and cancer cell-line models. RAPGEF1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAPGEF1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAPGEF1 RNA expression shows 20,247 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RAPGEF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPGEF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPGEF1 survival associations across molecular data types. RAPGEF1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPGEF1 RNA expression–survival associations across cancer types. High RAPGEF1 expression shows unfavorable associations in ACC, MESO, LUSC and LIHC, but favorable associations in KIRC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAPGEF1 RNA expression.
This table summarizes RAPGEF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAPGEF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPGEF1 shows lower tumor expression in LUAD, BRCA and COAD and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher RAPGEF1 RNA expression in tumor versus normal tissue (log2 FC = +0.961, t-test p < 0.001).
This table shows molecular features associated with RAPGEF1 in patient tissues and cancer cell lines. In patient samples, RAPGEF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAPGEF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
